Some Lyme disease patients report debilitating chronic symptoms of pain, fatigue, and cognitive deficits despite recommended courses of antibiotic treatment. The mechanisms responsible for these symptoms, collectively referred to as post-Lyme disease syndrome (PLS) or chronic Lyme disease, remain unclear. We investigated the presence of immune system abnormalities in PLS by assessing the levels of antibodies to neural proteins in patients and controls. Serum samples from PLS patients, post-Lyme disease healthy individuals, patients with systemic lupus erythematosus, and normal healthy individuals were analyzed for anti-neural antibodies by immunoblotting and immunohistochemistry. Anti-neural antibody reactivity was found to be significantly higher in the PLS group than in the post-Lyme healthy (p < 0.01) and normal healthy (p < 0.01) groups. The observed heightened antibody reactivity in PLS patients could not be attributed solely to the presence of cross-reactive anti-borrelia antibodies, as the borrelial seronegative patients also exhibited elevated anti-neural antibody levels. Immunohistochemical analysis of PLS serum antibody activity demonstrated binding to cells in the central and peripheral nervous systems. The results provide evidence for the existence of a differential immune system response in PLS, offering new clues about the etiopathogenesis of the disease that may prove useful in devising more effective treatment strategies.
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Introduction
Lyme disease is a multisystem infection, caused by bacteria of the Borrelia burgdorferi species complex and transmitted by Ixodes ticks (Stanek and Strle, 2003) . It is the most commonly reported tick-borne disease in the northern hemisphere, widespread in Europe and endemic in more than 15 states in the United States (Stanek and Strle, 2008; Steere, 2001 ). The initial skin rash (erythema migrans) may be followed by complications affecting joints, heart, and the nervous system (Stanek and Strle, 2003; Wormser et al., 2006) . The neurologic complications involve both the central and peripheral nervous systems. These include lymphocytic meningitis, encephalitis, cranial neuropathy, radiculopathy, and alterations of mental status, all of which usually respond well to antibiotic treatment (Halperin, 2008) . However, some patients with Lyme disease continue to have persistent complaints despite treatment and in the absence of objective evidence of infection, as determined by currently available methods (Feder et al., 2007; Marques, 2008) . The symptoms in these patients are generally accepted to include mild to severe musculokeletal pain, fatigue, and/or difficulties with concentration and memory (Feder et al., 2007; Marques, 2008) . The condition, variably referred to as chronic Lyme disease, post-treatment Lyme disease syndrome (PTLDS), and post-Lyme disease syndrome (PLDS or PLS), is associated with considerable impairment in the health-related quality of life in some patients (Klempner et al., 2001) .
Considering the lack of evidence for the presence of live spirochetes in PLS patients who have received recommended antibiotics, persistent infection is currently not thought to account for the symptoms of PLS by most investigators (Baker, 2008; Feder et al., 2007) . However, despite several years of debate and a number of treatment clinical trials (Fallon et al., 2008; Klempner et al., 2001; Krupp et al., 2003) , few clues to the causes of the symptoms have emerged. Lack of any biomarkers to aid in the diagnosis and follow-up has also compounded the problem of understanding the disease. Mechanisms other than active infection, including the possibility of involvement of adaptive or innate immune sys-
